How do these agreements impact post-market surveillance?

The legal manufacturer remains responsible for post-market surveillance. The agreement should define how service providers report adverse events, performance issues, or feedback to the manufacturer for analysis and regulatory reporting, which is crucial under regulations such as 21 CFR Part 803 and EU MDR Article 83.

What cybersecurity considerations apply to managed service offerings?

Cybersecurity responsibilities must be clearly delineated within the managed service contract. This includes defining who is responsible for patching, vulnerability management, access controls, and incident response, in line with FDA's

What cybersecurity considerations apply to managed service offerings?

Cybersecurity responsibilities must be clearly delineated within the managed service contract. This includes defining who is responsible for patching, vulnerability management, access controls, and incident response, in line with FDA's

All terms

CommercializationHospital Buyer & Reimbursement

Managed Service / Reagent Rental

Multi-year contract where instrument cost is bundled into per-test pricing.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

Managed service or reagent-rental contracts bundle the capital cost of an instrument into a fixed per-test or per-procedure price across a multi-year term, eliminating customer CapEx and locking in consumables share. Instead of buying an analyzer, a lab pays through reagent purchases or a per-test fee that covers the instrument and service. Contracts typically have minimum volume commitments and multi-year terms. Pricing must follow Anti-Kickback safe harbor rules where federal payers are involved.

What the regulation says

Managed service and reagent rental agreements are primarily commercial constructs. Regulatory bodies like the FDA or those governing EU MDR focus on the safety and performance of the medical devices involved, not directly on the financial arrangements. However, the service aspect implies responsibilities for device maintenance, servicing, and potentially software updates, which are covered under quality system regulations (e.g., 21 CFR 820.200 for servicing, ISO 13485:2016 clause 7.5.4 for service activities) to ensure continued compliance and patient safety.

What this means in practice

Standard in IVD, increasingly common in imaging AI and surgical capital. Revenue recognition (ASC 842 lease vs service) requires careful structuring.

Examples

A hospital enters into a managed service agreement for a new AI-powered diagnostic imaging system, where the vendor maintains the software, performs updates, and ensures data security.
A clinical laboratory utilizes a reagent rental agreement for an IVD analyzer, with the vendor providing the instrument and reagents, while also handling routine maintenance and calibration as part of the per-test fee.
A surgical center signs a managed service contract for robotic surgery equipment, where the manufacturer provides the robot, specialized instruments, and ongoing technical support and preventive maintenance.

Common pitfalls

•Confusing the commercial contract with regulatory obligations for device servicing and maintenance.
•Failing to establish clear responsibilities for software updates and cybersecurity patching in managed service agreements.
•Assuming that the financial arrangement absolves the legal manufacturer of post-market surveillance duties.
•Neglecting to consider the impact of service level agreements on device uptime and regulatory reporting requirements.
•Improperly classifying the service under financial accounting standards (e.g., ASC 842 if a lease rather than a service) can have audit and compliance implications.

Frequently asked questions

No, a managed service agreement does not alter the legal manufacturer's core responsibilities for ensuring the safety, efficacy, and quality of their medical device throughout its lifecycle, as stipulated by regulations like the EU MDR Annex I or FDA's 21 CFR Part 820.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Commercialization

Razor / Razor-Blade Model

Sell capital equipment at low margin; recurring consumables drive profit.

Market Segments

In Vitro Diagnostics(IVD)

Tests performed on biological samples outside the body.

Latest in MedTech

Sources

3 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 1Binding law and standards· 1Tier 4Trade press and expert commentary· 2

Link health: 3 verified· last checked 2026-06-20

FASB·1AdvaMed·1AHRMM·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Commercialization0 / 23

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Commercialization
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Multi-year contract where instrument cost is bundled into per-test pricing.

·Standard in IVD, increasingly common in imaging AI and surgical capital.
·Revenue recognition (ASC 842 lease vs service) requires careful structuring.
·Instead of buying an analyzer, a lab pays through reagent purchases or a per-test fee that covers the instrument and service.

Remember this

Watch out: Confusing the commercial contract with regulatory obligations for device servicing and maintenance.

Related terms

You may also need

Auto-suggested from Commercialization and shared keywords.

All Commercialization terms